Ignite Creation Date:
2026-03-26 @ 3:14 PM
Ignite Modification Date:
2026-07-09 @ 3:18 AM
Study NCT ID:
NCT07316361
Status:
ENROLLING_BY_INVITATION
Last Update Posted:
2026-01-07
First Post:
2025-12-08
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
GYNORYLAQ™-VLINIVAL™: Ψ-Guided Personalized Neoantigen Peptide Vaccine for High-Risk Endometrial Cancer
Sponsor:
Biogenea Pharmaceuticals Ltd.
Organization:
Conditions & Keywords Data
Conditions:
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Endometrial carcinoma | View |
| None | Personalized neoantigen vaccine | View |
| None | Peptide-based cancer immunotherapy | View |
| None | Quantum-classical vaccine design (GYNOLYVAQ-EC™) | View |
| None | Tumour-specific neoantigens | View |
| None | Immunogenicity and T-cell responses | View |
| None | Early phase I interventional clinical trial | View |